We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies.


Latest Post

July 13, 2016

USP Chapter 1207 Package Integrity Evaluation – Sterile Products

The challenge of assuring integrity of a sterile package is more complicated than many realize. As such, drug formulators in pharmaceutical and biotechnology companies often times underestimate the potential impact of the primary packages they select. A critical aspect to understand is container closure integrity (CCI) and leakage (i.e., failure of CCI or package integrity), is a major quality issue for sterile injectable products, as shown below.

Fran DeGrazio

VP, Scientific Affairs & Technical Services


Search the Blog





  • Previous Posts